Hypertension in a Population of Active Duty Service Members

References

1. ↵
   Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Archives Intern Med 2004; 164: 2126–34.

   OpenUrl
2. ↵
   Pfizer. The health status of the United States Army: findings from the Total Army Injury and Health Outcomes Database (TAIHOD). New York: Pfizer Inc.; 2003.
3. ↵
   Department of Defense Instruction 6130.4: “Criteria and Procedure Requirements for Physical Standards for Appointment, Enlistment, or Induction in the Armed Forces.” Washington (DC): U.S. Department of Defense; 2004.
4. ↵
   Department of Defense Directive 1308.1, “DoD Physical Fitness and Body Fat Program.” Washington (DC): U.S. Department of Defense; 2004.
5. ↵
   Department of Defense Instruction 1332.38, “Separation or Retirement for Physical Disability.” Washington (DC): U.S. Department of Defense; 1996.
6. ↵
   Hennessy BJ, Kerns DG, Davies WG. The incidence of active duty dental patients taking antihypertensive medications. Mil Med 1999; 164: 740–5.

   OpenUrlPubMed
7. ↵
   Johnson BW, Davies WG, Hardy DW, et al. A descriptive analysis of hypertension and affiliated therapies in a military retiree population (ages 40–85 years) at Camp Lejeune. North Carolina. Mil Med 2003; 168: 424–5.

   OpenUrl
8. ↵
   Army Regulation 40-501, “Standards of Medical Fitness.” Washington (DC): U.S. Department of the Army; 1998.
9. ↵
   Army Regulation 600-63, “Army Health Promotion.” Washington (DC): U.S. Department of the Army; 1996.
10. ↵
    VA/DoD Evidence-Based Clinical Practice Guideline Working Group, Veterans Health Administration, Department of Veterans Affairs, and Health Affairs, Department of Defense. Diagnosis and Management of Hypertension in the Primary Care Setting. Washington (DC): Office of Quality and Performance; 1999, 2004 (update).
11. ↵
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention. Detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–52.

    OpenUrl
12. ↵
    Kugler JP, Yeash J, Rumbaugh PC. The impact of sociodemographic, health care system, and family function variables on prenatal care utilization in a military setting. J Fam Pract 1993; 37: 143–7.

    OpenUrlPubMed
13. ↵
    Department of the Army. Army demographics FY00. Washington (DC): U.S. Department of the Army; 2000.
14. ↵
    SPSS 12.0.2 for Windows. Chicago: SPSS Inc.; 1989–2003.
15. ↵
    Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. Healthy People 2010 Stat Notes. 2001 Jan(20): 1–10.
16. ↵
    Verdecchia P, Schillaci G, Borgioni C, et al. White coat hypertension and white coat effect. Similarities and differences. Am J Hypertens 1995; 8: 790–8.

    OpenUrl
17. ↵
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    Qureshi AI, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 2005; 11: CR403–9.

    OpenUrlPubMedWeb of Science
19. ↵
    Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. Vital Health Stat 1 1994; Jul (32): 1–407.

    OpenUrl
20. ↵
    National Health and Nutrition Examination Survey Physician Examination Procedures Manual. Hyattsville (MD): National Center for Health Statistics; 1999 [updated 2000; cited 2006 December 30]. Available from: http://www.cdc.gov/nchs/about/major/nhanes/currentnhanes.htm.
21. ↵
    Marshall T. Misleading measurements: modeling the effects of blood pressure misclassification in a United States population. Med Decis Making 2006; 26: 624–32.

    OpenUrlAbstract/FREE Full Text
22. Perry HM, Jr, Miller JP. Difficulties in diagnosing hypertension: implications and alternatives. J Hypertens 1992; 10: 887–96.

    OpenUrlPubMedWeb of Science
23. Turner MJ, van Schalkwyk JM. Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study. Am J Hypertens 2008; 21: 85–91.

    OpenUrlAbstract/FREE Full Text
24. ↵
    Bland JM, Altman DG. Regression towards the mean. BMJ 1994; 308: 1499.

    OpenUrlFREE Full Text
25. ↵
    Bland JM, Altman DG. Some examples of regression towards the mean. BMJ 1994; 309: 780.

    OpenUrlFREE Full Text
26. ↵
    Mancia G, Bertinieri G, Grassi G, et al. Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet 1983; 2: 695–8.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti A. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9: 209–15.

    OpenUrlAbstract/FREE Full Text
28. ↵
    Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 1988; 259: 225–8.

    OpenUrlCrossRefPubMedWeb of Science
29. ↵
    Parati G, Mancia G. White coat effect: semantics, assessment and pathophysiological implications. J Hypertens 2003; 21: 481–6.

    OpenUrlCrossRefPubMed
30. ↵
    Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? Stroke 2005; 36: 1859–63.

    OpenUrlAbstract/FREE Full Text
31. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682–6.

    OpenUrlCrossRefPubMedWeb of Science
32. Winegarden CR. From “prehypertension” to hypertension? Additional evidence. Ann Epidemiol 2005; 15: 720–5.

    OpenUrlCrossRefPubMedWeb of Science
33. ↵
    Chiu YH, Wu SC, Tseng CD, Yen MF, Chen TH. Progression of pre-hypertension, stage 1 and 2 hypertension (JNC 7): a population-based study in Keelung. Taiwan (Keelung Community-based Integrated Screening No. 9). J Hypertens 2006; 24: 821–8.
34. ↵
    Zhang H, Thijs L, Kuznetsova T, Fagard RH, Li X, Staessen JA. Progression to hypertension in the non-hypertensive participants in the Flemish Study on Environment, Genes and Health Outcomes. J Hypertens 2006; 24: 1719–27.

    OpenUrlCrossRefPubMedWeb of Science
35. ↵
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.

    OpenUrlCrossRefPubMedWeb of Science
36. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294: 466–72.

    OpenUrlCrossRefPubMedWeb of Science
37. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. New Engl J Med 2001; 345: 1291–7.

    OpenUrlCrossRefPubMedWeb of Science
38. ↵
    Liszka HA, Mainous AG, 3rd, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann Fam Med 2005; 3: 294–9.

    OpenUrlAbstract/FREE Full Text
39. ↵
    Mainous AG, 3rd, Everett CJ, Liszka H, King DE, Egan BM. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol 2004; 94: 1496–500.

    OpenUrlCrossRefPubMedWeb of Science
40. ↵
    Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334: 885.

    OpenUrlAbstract/FREE Full Text
41. ↵
    Elliott WJ, Black HR. Prehypertension. Nat Clin Pract Cardiovasc Med 2007; 4: 538–48.

    OpenUrlCrossRefPubMed